Trombocitopenia imună refractară – prezentare de caz
Authors:
- Iuliana IordanIIIuliana Iordan
- Andreea NeculceaANAndreea Neculcea
- Stejara Nicoleta MihaiSMStejara Nicoleta Mihai
- Diana Emanuela BoneaDBDiana Emanuela Bonea
- Andreea SpînuASAndreea Spînu
- Alina MititeluAMAlina Mititelu
- Claudiu PopescuCPClaudiu Popescu
- Raluca TruicanRTRaluca Truican
- Anca NicolescuANAnca Nicolescu
- Ana Maria Prof. Dr. VlădăreanuAVAna Maria Prof. Dr. Vlădăreanu
Open Access
- 1 January 2022
- journal article
- Published by MedicHub Media in Oncolog-Hematolog.ro
- Vol. 2 (59) , 29
Abstract
Immune thrombocytopenia is an autoimmune disorder that involves the platelet destruction in the spleen. Often, patients do not respond to conventional therapy. The management of refractory or relapsed immune thrombocytopenia poses a challenge for hematologist. We report the case of a 43-year-old patient in whom conventional treatment was not successful but who responded to TPO agonist eltrombopag.Keywords
This publication has 5 references indexed in Scilit:
- Immune Thrombocytopenia (ITP): Current Limitations in Patient ManagementMedicina, 2020
- Idiopathic thrombocytopenic purpura (ITP) – new era for an old diseaseRomanian Journal of Internal Medicine, 2019
- Eltrombopag-based combination treatment for immune thrombocytopeniaTherapeutic Advances in Hematology, 2018
- Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safetyTherapeutic Advances in Drug Safety, 2018
- How I treat refractory immune thrombocytopeniaBlood, 2016